important source Wet Stormy Weather in San Francisco-A New Indicator for a Good Year Ahead?
About 8000+ investors, entrepreneurs and life science Company executives piled into the Westin St. Francis for the Annual J.P.Morgan Healthcare Conference and maybe 10k+ others at several other surrounding hotel venues to hear the latest updates on new products, deals and financial reports in biotechnology. The mood was more upbeat than last January which was one of the worst months ever.
Here are some hot stocks and related news:
http://sparkwebgroup.com/wp-login.php?redirect_to=http://sparkwebgroup.com/wp-admin/ Illumina (ILMN) soared 17.5% to $166 today after presenting their new product pipeline late on Monday. Guidance was also given for $2.660 B in Revenues for 2017 a 10-12% increase over 2016 with EPS of $3.25-3.35. Fourth quarter sales were $619 above consensus. Illumina (ILMN) launched the NovaSeq Series a new sequencing architecture that could tenable the $100 genome.The technology was improved through scalable design, a new high density flow cell and better optics. The cost for the 5000/6000 series is in the range of $850-980K. Sequencing data among users can be shared via the Cloud.
Mid Caps were strong yesterday with stocks climbing on clinical news with M&A themes triggered by the Ariad (ARIA) $5.2B buyout by Takeda announced yesterday. Incyte (INCY) is up 19% over 5 days to the $120 level. Incyte announced a deal with Merck for a pivotal study involving Keytruda, an anti-PD1 inhibitor with Epacadostat, an oral selective IDO1 inhibitor in four additional tumors.
ALNY and GWPH were also up today.Bargain hunters liked Regeneron (REGN) up 5% to $373.
http://viewtific.com/wp-includes/images/usacheck/finding-someone-bojozige.html Radius Health (RDUS) ran for a second day up 4% to $45.39. There was no news for the Company but investors liked the presentation on their pipeline of drugs in endocrinology and oncology. The Radius Health osteoporosis drug for post-menopausal women, isabaloparatide-SC is under regulatory review in the US and Europe with an FDA PDUFA date is March 30, 2017.
The rally today was not broad- based but the IBB and XBI eked out small gains of 0.8%.
Maybe this Trump news on ACA muted gains today.